Form 4: Century Therapeutics Executive Sells Shares Under 10b5-1 Trading Plan

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold 5,000 shares of common stock on June 20, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Gregory Russotti, the Chief Technology and Manufacturing Officer of Century Therapeutics, sold 5,000 shares of common stock on June 20, 2024.
• The sale was executed under a Rule 10b5-1 trading plan adopted on January 9, 2024.
• The shares were sold at a weighted average price of $2.8357, with individual transactions ranging from $2.685 to $2.985.
• Following the transaction, Russotti directly owns 277,319 shares and indirectly owns 92,773 shares through the Gregory Russotti 2021 Family Trust.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a stock sale by an executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 trading plan suggests the executive is selling shares in a pre-planned manner to avoid accusations of insider trading.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates